Article
In the past three years, the U.S. Food and Drug Administration has approved two medications for tardive dyskinesia, contributing to a resurgent interest in recognition, management, and treatment.
This Psychiatric Times® supplement provides a brief review of primarily recent literature on tardive dyskinesia, including signs and symptoms, risk factors and epidemiology, potential mechanisms, and screening and treatment.
Download Supplement
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.